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Introduction & Objectives 
Hyaluronic acid (HA) and chondroitin sulfate (CS) are two major constituents of the bladder 
glycosaminoglycan layer. Recent data show that Fibronectin (FN) and Epidermal Growth Factor 
Receptor (EGFR) gene expression can be measured in bladder washings and could represent 
potential biomarkers of urothelial damage and tumor aggressiveness, respectively (1,2). The aim of 
our study was to investigate the interference of a single intravesical instillation of HA-CS solution 
on the expression of FN and EGFR genes in patients affected by non-muscle-invasive bladder 
cancer (NMIBC). 
Material & Methods 
A prospective double-blinded study included patients undergoing adjuvant intravesical therapy for 
NMIBC and age matched healthy controls. For EGFR evaluation, a single HA-CS solution was 
administered intravesically 14 days after transurethral resection of high risk NMIBC, before the 
start of the adjuvant therapy. For FN evaluation, a single HA-CS instillation was administered to 
patients showing local toxicity secondary to intravesical adjuvant therapy. Samples of bladder 
washings were collected before and one week after the HA-CS instillation, obtaining a cellular 
pellet stored at -80 °C. Cellular RNA was isolated by a miRNeasy Mini Kit (Qiagen®) and cDNA, 
obtained using a “High Capacity cDNA Reverse Transcription Kit” (Life Technologies®) was used 
to perform a gene expression analysis by a Real Time PCR. EGFR and FN gene expression values 
were expressed in FOLDs of change compared to healthy controls (FN and EGFR=1). 
Results 
Thirty-eight patients and 5 controls entered the study. Seventeen and 21 patients were evaluated for 
FN and EGFR respectively. In 21 patients with high risk NMIBC, the median EGFR expression 
decreased from 2.4 folds (range: 0.1-39.0) to 1.0 fold (range: 0.05-36.8) showing a statistically 
significant decrease of 58.3% (p<0.02). In patients showing clinically relevant toxicity secondary to 
intravesical adjuvant therapy (BCG in 9 and Epirubicin in 8 patients) the median FN expression 
value dropped from 1.8 folds (range: 0.07-8.1) to 0.9 fold (range: 0.1-7.5) after HA-CS 
administration with a statistically significant decrease of 50% (p<0.05). 
Conclusions 
FN gene expression in bladder washings appears related to the intensity of the urothelial damage, 
reaching higher expression levels in case of severe toxicity induced by intravesical adjuvant therapy 
(2). In our experience the FN gene expression significantly decreases a week after the 
administration of HA-CS solution with contemporary symptomatic relief. Moreover the urothelial 
EGFR gene expression resulted significantly lowered one week after the HA-CS intravesical 
administration. The reduced availability of its receptor could limit the proliferative activity of EGF 
on the urothelium promoting recurrence and progression. 
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